Chinese biotechnology start-up GemPharmatech has raised RMB160 million (US$23.24 million) in a series A round of financing from investors including the country’s alternative asset management firm CDH Investments, according to a company statement.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?